Shaanxi BLOOM Tech Co., Ltd. yog ib qho ntawm cov tuam ntxhab thiab cov muag khoom ntawm lypressin cas 50-57-7 hauv Suav teb. Txais tos rau cov lag luam wholesale bulk zoo lypressin cas 50-57-7 muag ntawm no los ntawm peb lub hoobkas. Kev pabcuam zoo thiab tus nqi tsim nyog muaj.
Lypressinvasopressin (tseem hu ua vasopressin) yog 9-peptide hormone secreted los ntawm paj hlwb nyob rau hauv lub supraoptic thiab paraventricular nuclei ntawm lub hypothalamus, uas yog tso tawm tom qab mus txog rau lub posterior lobe ntawm lub neurohypophysis los ntawm lub hypothalamic pituitary ib ntsuj av. Cov mis mos molecular C46H65N13O12S2, CAS 50-57-7.
Nws feem ntau muaj nyob rau hauv daim ntawv ntawm dawb los yog me ntsis yellowish crystalline hmoov. Cov hmoov no ruaj khov ntawm chav tsev kub, tsis yooj yim hygroscopic, thiab yooj yim khaws thiab thauj. Nws daim ntawv yog amorphous hmoov, nrog zoo hais thiab zoo fluidity. Nws muaj qhov zoo solubility hauv dej thiab tuaj yeem tsim cov kua dej ntshiab thiab pob tshab. Nyob rau hauv cov pH sib txawv, nws solubility yuav txawv, tab sis nws feem ntau tuav ib tug siab solubility nyob rau hauv lub physiological pH ntau. Txawm li cas los xij, nws qhov kev ruaj ntseg yuav cuam tshuam rau qee qhov hauv qhov kub thiab txias los yog qhov chaw ntub dej.
Customized Bottle Caps Thiab Corks:
|
|
|
Cov Khoom Siv
lypressin COA
 |
||
| Certificate of Analysis | ||
| Compound npe | lypressin | |
| Qib | Pharmaceutical qib | |
| CAS Nr. | 50-57-7 | |
| Ntau | Customized | |
| Ntim txheem | Customized | |
| Chaw tsim tshuaj paus | Shaanxi BLOOM TECH Co., Ltd | |
| Ntau No. | 202501090065 | |
| MFG | Peb 9, 2026 | |
| EXP | Peb 8, 2029 | |
| Qauv |  |
|
| Yam khoom | Enterprise txheem | Kev txheeb xyuas qhov tshwm sim |
| Qhov tshwm sim | Dawb los yog yuav luag dawb hmoov | Ua raws |
| Cov ntsiab lus dej | Tsawg dua lossis sib npaug li 5.0% | 0.54% |
| Poob rau ziab | Tsawg dua lossis sib npaug li 1.0% | 0.42% |
| Hnyav Hlau | Pb Tsawg dua lossis sib npaug li 0.5ppm | N.D. |
| Tsawg dua lossis sib npaug li 0.5ppm | N.D. | |
| Hg Tsawg dua lossis sib npaug li 0.5ppm | N.D. | |
| Cd Tsawg dua lossis sib npaug li 0.5ppm | N.D. | |
| Purity (HPLC) | Ntau dua lossis sib npaug li 99.0% | 99.98% |
| Ib leeg impurity | <0.8% | 0.52% |
| Tag nrho microbial suav | Tsawg dua lossis sib npaug li 750cfu / g | 95 |
| E. Coli | Tsawg dua lossis sib npaug li 2MPN / g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (los ntawm GC) | Tsawg dua lossis sib npaug li 5000ppm | 500ppm ua |
| Cia | Khaws rau hauv qhov chaw kaw, tsaus, thiab qhuav hauv qab -20 degree | |
|
|
||
Yog li ntawd, thaum khaws cia thiab siv, yuav tsum tau saib xyuas kom tsis txhob muaj qhov kub thiab txias, tswj kom qhuav thiab huv. Qhov hnyav molecular me me tso cai rau nws nkag mus rau hauv cov cell membrane sai sai thiab siv nws cov teebmeem. Nws cov qauv molecular muaj ntau pawg ua haujlwm, suav nrog amide bonds, carboxyl pawg, thiab cov amino pawg, uas ua lub luag haujlwm tseem ceeb hauv cov tshuaj receptor khi thiab cov tshuaj metabolism hauv lub cev. Nws lub luag haujlwm tseem ceeb yog txhawm rau txhim kho qhov permeability ntawm lub raj xa dej mus rau dej, txhawb kev nqus dej, thiab yog ib qho tseem ceeb ntawm cov tshuaj hormones rau cov zis concentration thiab dilution. Tsis tas li ntawd, cov tshuaj no tseem tuaj yeem txhim kho qhov permeability ntawm lub hauv paus medullary sau duct rau urea.
Lypressinvasopressin (Lysiparessin) yog peptide compound synthesized los ntawm chemically modifying natural vasopressin (AVP). Nws cov yam ntxwv tseem ceeb yog kev hloov pauv ntawm arginine ntawm qhov chaw thib 8 ntawm qhov qub molecule nrog lysine, thiab tsim cov prodrug los ntawm kev khi peb glycerols ntawm N-terminus. Cov tshuaj no tso tawm cov khoom xyaw nquag tom qab enzymatic hydrolysis nyob rau hauv lub cev, xaiv activates V1 receptors ntawm vascular du nqaij thiab V2 receptors ntawm lub raum sau cov hlab ntsha epithelial hlwb, exerting pharmacological teebmeem xws li constriction ntawm visceral hlab ntsha, kev tswj ntawm portal siab, thiab txhawb dej reabsorption.
Kev Kho Mob: Cov ntsiab lus tseem ceeb thiab cov txheej txheem kho
1. Kev kho mob ntawm cov teeb meem ntawm daim siab cirrhosis
(1) esophageal variceal los ntshav
Los ntawm kev ua kom lub visceral vascular du nqaij V1 receptor, portal leeg ntshav khiav yog txo los ntawm 35%, txo qhov kev pheej hmoo ntawm varicose leeg rupture. Cov kev sim tshuaj ntsuam xyuas tau pom tias nws qhov kev ua tau zoo hauv kev tswj tus mob esophageal variceal los ntshav yog 76% -85%, ntau dua li cov tshuaj ib txwm siv (xws li 65% -70% ntawm somatostatin analogs). Cov txheej txheem yog xaiv kev cog lus rau cov hlab ntsha splenic thaum dilating lub raum cov hlab ntsha, ua kom cov glomerular pom tus nqi los ntawm 56%, tswj lub raum perfusion thaum txo qhov portal siab, thiab txo qhov kev pheej hmoo ntawm hepatorenal syndrome.
(2) Hepatorenal syndrome
Nyob rau hauv ib tug multicenter txoj kev tshawb no ua nyob rau hauv 2017, tag nrho remission tus nqi ntawm cov ntshav creatinine nyob rau hauv cov neeg mob uas muaj hepatorenal syndrome yog 56%, uas yog 11 lub sij hawm ntau dua li cov tswj pawg (5%). Nws txo cov hnyuv congestion thiab txhim kho lub raum hemodynamics los ntawm constricting visceral hlab ntsha, thaum inhibiting renin -angiotensin system kev ua si thiab txo lub raum vascular kuj. Tus txheej txheem kev noj tshuaj yog txhaj tshuaj 1-2mg txhua 4-6 teev, thiab cov ntshav sodium yuav tsum tau saib xyuas kom tsis txhob muaj qhov tsis txaus electrolyte.
2. Cov tswv yim pab rau kev kho mob poob siab
(1) Septic shock
Kev txhim kho lub cev perfusion los ntawm kev ua kom lub cev siab (MAP) yog qhov tshwj xeeb tshaj yog rau cov neeg mob uas tsis teb rau cov kua dej resuscitation. Piv nrog rau norepinephrine, qhov tshwm sim ntawm cov kev phiv tshwm sim xws li coronary artery constriction raug txo mus rau 2.3%, thiab nws tsis ua rau kom myocardial oxygen noj. Ib qho kev soj ntsuam randomized uas muaj 200 tus neeg mob tau pom tias kev siv vasopressin ua ke tuaj yeem ua rau cov pa oxygenation Performance index (PaO ₂ / FiO ₂) los ntawm (180 ± 30) mmHg rau (250 ± 40) mmHg thiab ua kom lub sijhawm ua pa ntawm lub tshuab ua pa los ntawm 40%.
(2) Cardiogenic poob siab
Nyob rau hauv kev kho mob xwm txheej ceev ntawm mob myocardial infarction nyuaj nrog cardiogenic poob siab, nws ua rau cov hlab ntsha peripheral tswj vasoconstriction, zoo txo cov ntshav siab, txo qis sab laug ventricular preload, thiab txhim kho myocardial contractility tsis muaj zog. Cov kev sim tshuaj tsiaj muaj feem cuam tshuam tau txheeb xyuas nws qhov ua tau zoo, lees paub tias nws tuaj yeem ua rau lub plawv nce ntxiv los ntawm 15% -20%.
Cov cim tshwj xeeb: los ntawm cov kab mob hauv qab mus rau kev coj cwj pwm
1. Kev kho mob ntshav qab zib insipidus sib txawv
(1) Central ntshav qab zib insipidus
Lysine vasopressin tsuag (1-2 tshuaj txhua zaus, 3-5 zaug hauv ib hnub) tuaj yeem txhawb nqa cov dej rov qab los ntawm lub raum tubules los ntawm kev ua kom V2 receptor, thiab txo cov zis ntim los ntawm 50% -70%. Nws cov nyhuv antidiuretic yog kwv yees li 50% muaj zog dua li ntuj AVP, tab sis nws cov khoom vasoconstrictive tsuas yog tshwm sim ntawm cov koob tshuaj siab, ua rau nws muaj kev nyab xeeb rau cov neeg mob me me. Ib txoj kev tshawb nrhiav mus ntev tau pom tias cov ntshav sodium concentration ntawm cov neeg mob noj cov tshuaj raws li kev cai tseem nyob ruaj khov ntawm (140 ± 5) mmol / L, thiab qhov zaus ntawm lub cev qhuav dej tau txo qis los ntawm 80%.
(2) raum ntshav qab zib insipidus
Vim qhov tsis ua haujlwm ntawm V2 receptors hauv cov neeg mob lub raum mob ntshav qab zib insipidus, cov nyhuv kho tau txwv, tab sis nws tuaj yeem txhim kho los ntawm kev siv cov tshuaj thiazide diuretics (xws li hydrochlorothiazide). Cov txheej txheem yog tias thiazide tebchaw tsis ncaj qha nce qhov kev qhia ntawm aquaporin 2 (AQP2) los ntawm kev txo lub raum tubular sodium reabsorption, thiab muaj cov nyhuv synergistic nrog lysine vasopressin.
2. Kev tshawb nrhiav kev siv ntawm cov haujlwm neurobiological
(1) Kev cai tsiaj txhu
Hauv cov qauv nyom vole, thaiv lub paj hlwb vasopressin receptor ua rau 90% ntawm cov tib neeg poob qhov tshwj xeeb rau lawv tus txij nkawm qub.
Kev txhaj tshuaj ntxiv ntawm cov tshuaj no tuaj yeem rov qab muaj peev xwm paub txog tus khub hauv kev sim nas. Cov txheej txheem yuav cuam tshuam nrog "kev sib koom ua ke tshuaj lom neeg" cov nyhuv ntawm dopamine tso tawm hauv hypothalamus, muab cov qauv piav qhia qib molecular rau kev kawm txog tsiaj txhu kev coj noj coj ua.
(2) Kev tiv thaiv kev raug mob
Hauv kev sim nas kub phaj, qhov latency ntawm tus Tsov tus tw flick cov tshuaj tiv thaiv tau ntev heev (los ntawm 5.2 vib nas this mus rau 8.7 vib nas this), uas tau ua tiav los ntawm activating V1 receptor nyob rau hauv spinal dorsal horn neurons. Tsis tas li ntawd, nyob rau hauv uterine nqaij txheej ntawm npua, nws muaj peev xwm txhim khu kev contractility los ntawm kev nce intracellular calcium ion concentration, tawm tswv yim muaj peev xwm siv nyob rau hauv obstetrics.
Kev sib npaug tshuaj lom neeg rau kev sib txuas ntawm precursor peptide chains thiab cov kauj ruam hloov kho tom ntej (qhia hauv daim ntawv yooj yim)
-Activated amino acids: H2N-AA1-COOH+ activator → AA1-O-activator
-Activated peptide saw: AA1-O-activator+H2N-AA2-COOH → AA1-AA2-O-activator
- Rov ua dua cov kauj ruam saum toj no kom txog rau thaum ua tiav cov khoom ua ntej peptide saw txuas.
- Tshem tawm cov pab pawg tiv thaiv: Dmoc Arg → Arg
-Oxidation reaction: AA1-AA2-AA3-S-AA4-AA5 → AA1-AA2-AA3-S-AA4-AA5
-Kev tawg thiab recrystallization: AA1-AA2-AA3-S-AA4-AA5+ kuab tshuaj → Crystals
-Separation and purification: Crystals+separation and purification reagents ->Vasopressin ntshiab
Nws yuav tsum tau muab sau tseg hais tias lub laboratory synthesis txoj kev ntawmLypressinyog complex thiab cumbersome, thiab tej zaum yuav muaj kev sim tej yam kev mob thiab reagent xaiv. Yog li ntawd, nyob rau hauv kev ua hauj lwm, tej zaum yuav muaj ib co ncauj lus kom ntxaws cov kauj ruam thiab cov tshuaj tiv thaiv tej yam kev mob uas yuav tsum tau kho thiab optimized raws li tej yam kev mob.
Daim Ntawv Thov Kev Tshawb Fawb: Cov cuab yeej siv tshuaj thiab kev tsim qauv
Receptor pharmacology tshawb fawb:
Raws li ib qho kev xaiv agonist ntawm V1 / V2 receptors, nws yog dav siv hauv receptor binding thwmsim. Nws affinity rau V1 receptors yog peb zaug ntawm V2 receptors, ualypressinFeem ntau siv los paub qhov txawv receptor subtype functions. Piv txwv li, nyob rau hauv ex vivo vascular strip sim, nws muaj peev xwm cog lus nas aortic rings nyob rau hauv ib tug concentration nyob ntawm seb (EC50=0.3nM), thaum nws antidiuretic nyhuv yuav tsum tau ib tug ntau dua concentration (EC50=10nM).
Kev tsim kho cov qauv kab mob:
Nyob rau hauv tus qauv nas ntawm portal hypertension tshwm sim los ntawm cirrhosis, nruam infusion ntawm vasopressin (0.1mg / kg / h) tuaj yeem txo cov hlab ntshav siab ntawm (18 ± 2) cmH ₂ O rau (12 ± 1) cmH2O yam tsis ua rau cov ntshav siab hloov pauv. Cov qauv no muab lub platform ruaj khov rau kev ntsuas cov tshuaj tshiab portal antihypertensive.
Intermediate rau tshuaj synthesis:
Nws tuaj yeem siv los ua qhov tseem ceeb nruab nrab rau kev sib txuas ntawm terlipressin (N - - triglycosyl-8-lysine-pressin). Terlipressin ncua nws ib nrab-lub neej mus rau 6 teev los ntawm kev hloov kho triglyceride thiab yog thawj kab tshuaj rau kev kho mob variceal los ntshav hauv daim siab cirrhosis. Hauv 2023, lub ntiaj teb kev lag luam loj ntawm terlipressin yuav ncav cuag 1.2 billion US dollars, nrog rau lysine vasopressin intermediates accounting rau ntau tshaj 30%.
Vasopressin (AVP) yog ib qho tseem ceeb endogenous neuropeptide hormone uas muaj cov haujlwm xws li tswj cov dej sib npaug, vasoconstriction, thiab tiv thaiv diuresis hauv tib neeg lub cev.
Lub chaw soj nstuam synthesis feem ntau suav nrog ob kauj ruam tseem ceeb: kev sib txuas ntawm precursor peptide chains thiab kev hloov kho tom ntej. Cov hauv qab no yog cov kauj ruam ntxaws:
Kauj ruam 1: Synthesize precursor peptide chains
1. Xaiv cov pab pawg tiv thaiv tsim nyog thiab cov activators los ua ke cov khoom ua ntej peptide saw ntawm AVP los ntawm cov khoom sib txuas-theem synthesis.
2. Thaum lub sij hawm txheej txheem synthesis, lysine raug tiv thaiv raws li qhov xav tau, xws li los ntawm kev xaiv dimethylsilyl (Dmoc) los tsim cov saw peptide tiv thaiv.
3. Siv cov activators tsim nyog (xws li carbon disulfide thiab dimethylpyrrolidone) txhawm rau qhib cov amino acids thiab txuas cov saw peptide tiv thaiv nrog lwm cov amino acids; Rov ua cov kauj ruam saum toj no kom txog thaum ua tiav cov saw peptide ua ke.
Kauj Ruam 2: Kev hloov kho tom ntej
Tom qab lub synthesis ntawm precursor peptide saw tiav lawm, yuav tsum tau hloov kho cov kauj ruam tom ntej, nrog rau kev tiv thaiv, oxidation, dissolution, thiab recrystallization.
Tshem tawm cov pab pawg tiv thaiv ntawm lysine. Cov tshuaj tiv thaiv tsim nyog xws li trifluoroacetic acid (TFA) tuaj yeem siv los tshem tawm Dmoc pawg tiv thaiv los ntawm lysine, ua rau tsis muaj kev tiv thaiv lysine.
Ua cov tshuaj tiv thaiv oxidation. Los ntawm kev siv cov oxidants tsim nyog xws li acetic acid hydrogen peroxide (AcOH / H2O2), lub precursor peptide chains undergo oxidation cov tshuaj tiv thaiv los tsim disulfide bonds.
Dissolve thiab recrystallize cov khoom oxidized los txhim kho purity.Thaum kawg, los ntawm kev sib cais tsim nyog thiab purification technologies, xws li chromatography, gel filtration chromatography, thiab lwm yam., ntshiab lysine vasopressin yog tau.
FAQ
Dab tsi yog qhov tseem ceeb sib txawv hauv physiological adaptation ntawmlypressinthiab endogenous arginine vasopressin hauv tib neeg lub cev?
+
-
Teb: Cov tshuaj nquag yog nyob rau hauv cuaj peptide configuration, thiab nws cov molecular sequence yog heev homologous rau lub ntuj antidiuretic yam muab tau los ntawm npua. Nws tsuas yog muaj qhov sib txawv me ntsis ntawm cov amino acid kev npaj ntawm cov chaw tshwj xeeb nrog arginine vasopressin, uas yog lub ntsiab tswj hwm dej thiab ntsev hauv tib neeg lub cev; Lub physiological functions ntawm ob yog converging, tab sis Lypressin yog ntau ze ze rau lub physiological atherosclerosis ntawm cov tsiaj. Thaum ua ntawv thov rau tib neeg lub cev, nws tsuas yog ua haujlwm hloov pauv thiab tsis tuaj yeem ua kom tag nrho lub ntiaj teb kev tswj hwm kev noj qab haus huv ntawm endogenous arginine vasopressin.
Tsis yog txhua tus tsos mob ntawm polyuria tuaj yeem cuam tshuam nrog nws. Yuav ua li cas kom paub qhov txawv qhov siv tau hauv nruab nrab ntshav qab zib insipidus?
+
-
Teb: Cov tshuaj no tsuas yog ua haujlwm rau lub hauv paus tswj kev tsis muaj peev xwm ntawm hom ntshav qab zib insipidus, uas yog tshwm sim los ntawm kev cuam tshuam ntawm kev sib txuas thiab tso tawm cov tshuaj endogenous antidiuretic active tshuaj hauv lub cev; Txawm li cas los xij, nephrogenic mob ntshav qab zib insipidus yog tshwm sim los ntawm kev ua tsis tiav ntawm lub raum receptor teb nws tus kheej. Txawm hais tias exogenous antidiuretic peptide tshuaj ntxiv, nws tsis tuaj yeem txhim kho cov tsos mob ntawm polyphagia thiab polyuria, thiab tsis koom nrog qhov kev hloov pauv ntawm cov tshuaj no.
Vim li cas qhov no tsuas yog siv los ua ib qho kev ntsuas kub ntxhov ib ntus los tswj cov ntshav me me los ntawm cov kab mob esophageal varices thiab kho tsis tau?
+
-
Teb: Cov tshuaj no tsuas yog tso siab rau kev tswj hwm vascular tone thiab pab txhim kho lub zog coagulation hauv zos kom tsis txhob los ntshav ib ntus, thiab tsis hloov cov organic hauv paus ntawm esophageal venous tortuosity thiab dilation; Nws tsuas yog siv tau raws li luv luv - lub sij hawm hemostatic tsis nyob rau lub sij hawm mob hnyav los ua txoj hauv kev rau kev kuaj mob tom qab thiab kev kho mob xws li endoscopy thiab phais, thiab tsis tuaj yeem tshem tawm cov kev phom sij zais ntawm cov hlab ntsha.
Cim npe nrov: Lypressin CAS 50-57-7, lwm tus neeg, manufacturers, hoobkas, lag luam wholesale, yuav, nqe, tej, kev muag khoom